期刊
METABOLISM-CLINICAL AND EXPERIMENTAL
卷 64, 期 1, 页码 146-156出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.metabol.2014.07.014
关键词
Congenital leptin deficiency; Leptin; Metreleptin; Myalept; Obesity
资金
- Australian National University institutional grants
- NIH [RR-16996, HG-002500, DK-58851, RR-017611, K24-RR-016996]
Leptin has key roles in the regulation of energy balance, body weight, metabolism, and endocrine function. Leptin levels are undetectable or very low in patients with lipodystrophy, hypothalamic amenorrhea, and congenital leptin deficiency (CLD) due to mutations in the leptin gene. For these patients, leptin replacement therapy with metreleptin (a recombinant leptin analog) has improved or normalized most of their phenotypes, including normalization of endocrine axes, decrease in insulin resistance, and improvement of lipid profile and hepatic steatosis. Remarkable weight loss has been observed in patients with CLD. Due to its effects, leptin therapy has also been evaluated in conditions where leptin levels are normal or high, such as common obesity, diabetes (types 1 and 2), and Rabson-Mendenhall syndrome. Abetter understanding of the physiological roles of leptin may lead to the development of leptin-based therapies for other prevalent disorders such as obesity-associated nonalcoholic fatty liver disease, depression and dementia. (C) 2015 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据